Pharmaceutical firm AstraZeneca has unveiled plans to slash costs by 1.5 billion US dollars (£1.1 billion) a year as part of a major restructuring to boost investment in its new drug pipeline.
The London-listed group said the three-year overhaul would cost it up to two billion dollars (£1.5 billion) in restructuring charges, but declined to provide details on where the savings would come from and whether jobs would be impacted.
